Search clinical trials for: Volasertib

Total 18 results

Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
Boehringer Ingelheim

Completed

Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known

Neoplasms | Leukemia

Germany, France, Italy, Belgium, Czechia
Boehringer Ingelheim

Completed

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Japan
Boehringer Ingelheim

Completed

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

Neoplasms

Belgium
Anne Beaven, MD
Boehringer Ingelheim; National Comprehensive Cancer Network

Withdrawn

Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

CTCL | PTCL
Boehringer Ingelheim

Withdrawn

A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed

Leukemia, Myeloid, Acute

Belgium
Boehringer Ingelheim

Completed

Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

Japan
Yale University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Massey Cancer Center

Withdrawn

Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas

Lymphoma | Relapsed and Refractory Aggressive B- and T-cell Lymphomas

United States
Boehringer Ingelheim

Terminated

Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

France, Germany
Boehringer Ingelheim

Terminated

Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Japan
Boehringer Ingelheim

Terminated

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Boehringer Ingelheim

Completed

Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia

Leukemia, Myeloid, Acute

Canada, Norway, Belgium, Germany, Italy, Austria, France
Boehringer Ingelheim

Completed

Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)

Leukemia, Myeloid, Acute

Korea, Republic of, Spain, Canada, Germany, Norway, Taiwan, Belgium, United States, Japan, Mexico, France, Greece, Italy, India, Austria, Portugal, Czechia, Russian Federation, Hungary, Brazil, Argentina, Finland, Netherlands, Poland, South...
Northwestern University
National Cancer Institute (NCI); National Comprehensive Cancer Network

Withdrawn

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia

United States
University of Alberta

Withdrawn

A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC)

Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Acute | Leukemia, Monocytic, Acute | Leukemia, Megakaryoblastic, Acute | Leukemia, Erythroblastic, Acute

Canada
Massachusetts General Hospital
Boehringer Ingelheim

Withdrawn

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

AML

United States
Boehringer Ingelheim

Completed

Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours

Neoplasms

Hungary
University of Ulm

Terminated

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Germany

Search clinical trials for: Volasertib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations